These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21393461)

  • 1. A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
    Li P; Lu C; Balani SK; Gan LS
    Drug Metab Dispos; 2011 Jun; 39(6):1054-7. PubMed ID: 21393461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.
    Perloff ES; Mason AK; Dehal SS; Blanchard AP; Morgan L; Ho T; Dandeneau A; Crocker RM; Chandler CM; Boily N; Crespi CL; Stresser DM
    Xenobiotica; 2009 Feb; 39(2):99-112. PubMed ID: 19255936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs.
    Zimmerlin A; Trunzer M; Faller B
    Drug Metab Dispos; 2011 Jun; 39(6):1039-46. PubMed ID: 21383203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors.
    Dasgupta M; Tang W; Caldwell GW; Yan Z
    Rapid Commun Mass Spectrom; 2010 Aug; 24(15):2177-85. PubMed ID: 20583325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
    Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
    Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
    Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
    Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.
    Parkinson A; Kazmi F; Buckley DB; Yerino P; Paris BL; Holsapple J; Toren P; Otradovec SM; Ogilvie BW
    Drug Metab Dispos; 2011 Aug; 39(8):1370-87. PubMed ID: 21525169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
    Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
    Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
    Zhao P; Lee CA; Kunze KL
    Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
    Thelingwani RS; Zvada SP; Dolgos H; Ungell AL; Masimirembwa CM
    Drug Metab Dispos; 2009 Jun; 37(6):1286-94. PubMed ID: 19299526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
    Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
    Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring concepts of in vitro time-dependent CYP inhibition assays.
    Stresser DM; Mao J; Kenny JR; Jones BC; Grime K
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):157-74. PubMed ID: 24256452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction.
    Doshi U; Li AP
    J Biomol Screen; 2011 Sep; 16(8):903-9. PubMed ID: 21832258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    Grime KH; Bird J; Ferguson D; Riley RJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach.
    Mukadam S; Tay S; Tran D; Wang L; Delarosa EM; Khojasteh SC; Halladay JS; Kenny JR
    Drug Metab Lett; 2012 Mar; 6(1):43-53. PubMed ID: 22372554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition.
    Meisenheimer PL; Uyeda HT; Ma D; Sobol M; McDougall MG; Corona C; Simpson D; Klaubert DH; Cali JJ
    Drug Metab Dispos; 2011 Dec; 39(12):2403-10. PubMed ID: 21890735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.